Predicting Resolvin D1 Pharmacokinetics in Humans with Physiologically-Based Pharmacokinetic Modeling. 2021

Venkata K Yellepeddi, and Kaustubh Parashar, and Spencer M Dean, and Kevin M Watt, and Jonathan E Constance, and Olga J Baker
Division of Clinical Pharmacology, Department of Pediatrics, School of Medicine, University of Utah, Salt Lake City, Utah, USA.

Sjögren's syndrome (SS) is an autoimmune disease with no effective treatment options. Resolvin D1 (RvD1) belongs to a class of lipid-based specialized pro-resolving mediators that showed efficacy in preclinical models of SS. We developed a physiologically-based pharmacokinetic (PBPK) model of RvD1 in mice and optimized the model using plasma and salivary gland pharmacokinetic (PK) studies performed in NOD/ShiLtJ mice with SS-like features. The predictive performance of the PBPK model was also evaluated with two external datasets from the literature reporting RvD1 PKs. The PBPK model adequately captured the observed concentrations of RvD1 administered at different doses and in different species. The PKs of RvD1 in virtual humans were predicted using the verified PBPK model at various doses (0.01-10 mg/kg). The first-in-human predictions of RvD1 will be useful for the clinical trial design and translation of RvD1 as an effective treatment strategy for SS.

UI MeSH Term Description Entries
D008297 Male Males
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D004281 Docosahexaenoic Acids C22-unsaturated fatty acids found predominantly in FISH OILS. Docosahexaenoate,Docosahexaenoic Acid,Docosahexenoic Acids,Docosahexaenoic Acid (All-Z Isomer),Docosahexaenoic Acid Dimer (All-Z Isomer),Docosahexaenoic Acid, 3,6,9,12,15,18-Isomer,Docosahexaenoic Acid, 4,7,10,13,16,19-(All-Z-Isomer),Docosahexaenoic Acid, 4,7,10,13,16,19-(All-Z-Isomer), Cerium Salt,Docosahexaenoic Acid, 4,7,10,13,16,19-(All-Z-Isomer), Cesium Salt,Docosahexaenoic Acid, 4,7,10,13,16,19-(All-Z-Isomer), Potassium Salt,Docosahexaenoic Acid, 4,7,10,13,16,19-(Z,Z,Z,Z,Z,E-Isomer),Docosahexaenoic Acid, 4,7,10,13,16,19-Isomer,Docosahexaenoic Acid, 4,7,10,13,16,19-Isomer, Sodium Salt,Docosahexaenoic Acid, Sodium Salt,Acid, Docosahexaenoic,Acids, Docosahexaenoic,Acids, Docosahexenoic
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012469 Salivary Glands Glands that secrete SALIVA in the MOUTH. There are three pairs of salivary glands (PAROTID GLAND; SUBLINGUAL GLAND; SUBMANDIBULAR GLAND). Gland, Salivary,Glands, Salivary,Salivary Gland
D012859 Sjogren's Syndrome Chronic inflammatory and autoimmune disease in which the salivary and lacrimal glands undergo progressive destruction by lymphocytes and plasma cells resulting in decreased production of saliva and tears. The primary form, often called sicca syndrome, involves both KERATOCONJUNCTIVITIS SICCA and XEROSTOMIA. The secondary form includes, in addition, the presence of a connective tissue disease, usually rheumatoid arthritis. Sicca Syndrome,Sjogren Syndrome,Sjogrens Syndrome,Syndrome, Sicca,Syndrome, Sjogren's

Related Publications

Venkata K Yellepeddi, and Kaustubh Parashar, and Spencer M Dean, and Kevin M Watt, and Jonathan E Constance, and Olga J Baker
December 2019, CPT: pharmacometrics & systems pharmacology,
Venkata K Yellepeddi, and Kaustubh Parashar, and Spencer M Dean, and Kevin M Watt, and Jonathan E Constance, and Olga J Baker
December 2010, Journal of nanoscience and nanotechnology,
Venkata K Yellepeddi, and Kaustubh Parashar, and Spencer M Dean, and Kevin M Watt, and Jonathan E Constance, and Olga J Baker
January 2014, Frontiers in pharmacology,
Venkata K Yellepeddi, and Kaustubh Parashar, and Spencer M Dean, and Kevin M Watt, and Jonathan E Constance, and Olga J Baker
February 2019, European journal of drug metabolism and pharmacokinetics,
Venkata K Yellepeddi, and Kaustubh Parashar, and Spencer M Dean, and Kevin M Watt, and Jonathan E Constance, and Olga J Baker
January 2016, Drug design, development and therapy,
Venkata K Yellepeddi, and Kaustubh Parashar, and Spencer M Dean, and Kevin M Watt, and Jonathan E Constance, and Olga J Baker
October 2016, Clinical therapeutics,
Venkata K Yellepeddi, and Kaustubh Parashar, and Spencer M Dean, and Kevin M Watt, and Jonathan E Constance, and Olga J Baker
October 2003, Journal of pharmaceutical sciences,
Venkata K Yellepeddi, and Kaustubh Parashar, and Spencer M Dean, and Kevin M Watt, and Jonathan E Constance, and Olga J Baker
March 2022, Regulatory toxicology and pharmacology : RTP,
Venkata K Yellepeddi, and Kaustubh Parashar, and Spencer M Dean, and Kevin M Watt, and Jonathan E Constance, and Olga J Baker
August 2006, Risk analysis : an official publication of the Society for Risk Analysis,
Venkata K Yellepeddi, and Kaustubh Parashar, and Spencer M Dean, and Kevin M Watt, and Jonathan E Constance, and Olga J Baker
July 2017, Oncotarget,
Copied contents to your clipboard!